Is CYP2C19 useful for skin aging?

There is currently no strong evidence that CYP2C19 is useful for assessing or managing skin aging. CYP2C19 is a well-characterized drug-metabolizing enzyme primarily expressed in the liver; its genetic variants (e.g., rs4244285, CYP2C19*2) affect the metabolism of medications like clopidogrel and proton pump inhibitors. While CYP2C19 is also expressed in skin, its direct role in collagen degradation, oxidative stress, or elastin maintenance is not supported by human studies. Direct-to-consumer tests that market CYP2C19 results in the context of 'longevity' or skin health are misleading. Even if a consumer receives a result, there are no validated interventions—topical or oral—based on this gene for skin aging. The evidence level is 'unclear' at best, with only mechanistic speculation. Consumers should rely on proven skin-aging strategies: sun protection, balanced nutrition, and lifestyle factors. Safety note: CYP2C19 status is relevant only for pharmacogenetic guidance; any medication changes require clinical-grade confirmation.